[Federal Register Volume 86, Number 218 (Tuesday, November 16, 2021)]
[Notices]
[Page 63405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24895]
[[Page 63405]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services is hereby
giving notice that the Advisory Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a virtual meeting. The meeting will
be open to the public. For this meeting, the committee will discuss and
vote on a recommendation pertaining to a proposed update to the 2020
Public Health Service (PHS) Guideline for Assessing Solid Organ Donors
and Monitoring Transplant Recipients for Human Immunodeficiency Virus,
Hepatitis B Virus, and Hepatitis C Virus Infection. The following
question will be posed to the committee: Does the available data
support exempting solid organ transplant candidates who are <=10 years
of age at the time of transplant (and who have received postnatal
infectious disease testing) from the recommendation for HIV, Hepatitis
B virus, and Hepatitis C virus testing during the hospital admission
for transplant but prior to anastomosis of the first organ?
DATES: The meeting will take place virtually on Wednesday, December 1,
2021 from approximately 11:00 a.m.-3:00 p.m. Eastern Time (ET). Meeting
times are tentative and subject to change. The confirmed times and
agenda items for the meeting will be posted on the ACBTSA web page at
https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-12-01/index.html when this information
becomes available.
FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS
Policy, Office of the Assistant Secretary for Health, Department of
Health and Human Services, Mary E. Switzer Building, 330 C Street SW,
Suite L600, Washington, DC 20024. (202) 795-7608 or Email:
[email protected].
SUPPLEMENTARY INFORMATION: The ACBTSA is a discretionary Federal
advisory committee. The Committee is governed by the provisions of the
Federal Advisory Committee Act (FACA), Public Law 92-463, as amended (5
U.S.C. App), which sets forth standards for the formation and use of
advisory committees. On the day of the meeting, please go to https://www.hhs.gov/live/index.html to view the meeting. The public will have
an opportunity to present their views to the ACBTSA by submitting a
written public comment. Comments should be pertinent to the meeting
discussion. Persons who wish to provide written public comment should
review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-12-01/index.html and
respond by midnight November 26, 2021, ET. Written public comments will
be accessible to the public on the ACBTSA web page prior to the
meeting.
ACBTSA functions to provide advice to the Secretary through the
Assistant Secretary for Health on a range of policy issues to include:
(1) Identification of public health issues through surveillance of
blood and tissue safety issues with national survey and data tools; (2)
identification of public health issues that affect availability of
blood, blood products, and tissues; (3) broad public health, ethical,
and legal issues related to the safety of blood, blood products, and
tissues; (4) the impact of various economic factors (e.g., product cost
and supply) on safety and availability of blood, blood products, and
tissues; (5) risk communications related to blood transfusion and
tissue transplantation; and (6) identification of infectious disease
transmission issues for blood, organs, blood stem cells and tissues.
The Committee has met regularly since its establishment in 1997.
Dated: October 27, 2021.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue
Safety and Availability, Office of Infectious Disease and HIV/AIDS
Policy.
[FR Doc. 2021-24895 Filed 11-15-21; 8:45 am]
BILLING CODE 4150-28-P